Mitigation of TAEs, vein-to-vein. The figure highlights roles of the donor, blood product, and patient in the mitigation of TAEs. Some examples highlighted in this figure include (1) the recruitment of group O, Rh-negative blood donors for massive hemorrhaging patients, (2) the recruitment of specific RBC antigen phenotypes for chronically transfused patients to prevent hemolytic transfusion reactions (eg, sickle cell disease patients), (3) vein-to-vein data to investigate the influence of the donor (eg, age, race/ethnicity, and sex) and product characteristics (eg, hemolysis) on patient outcomes (eg, posttransfusion increment, TRALI), (4) continued investigation of the harmful effects of plastics (eg, di(2-ethylhexyl)phthalate [DEHP]) in patients, especially neonates, and (5) continued development of new storage solutions or conditions that improve the RBC storage lesion.